메뉴 건너뛰기
Critical Care Medicine
Volumn 32, Issue 11, 2004, Pages 2348-2349
Activated protein C: Beyond 28 days
Author keywords

Mortality; PROWESS study; Sepsis
Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN;
EID: 8544268685     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000146137.32072.F7     Document Type: Editorial
Times cited : (1)
References (8)
  • 1
    • 0029092928 scopus 로고
    • Sepsis trials: Intersection of investigation, regulation, funding, and practice
    • Bernard GR: Sepsis trials: Intersection of investigation, regulation, funding, and practice. Am J Respir Crit Care Med 1995; 154:4-10
    • (1995) Am J Respir Crit Care Med , vol.154 , pp. 4-10
    • Bernard, G.R.1
  • 2
    • 0035826096 scopus 로고    scopus 로고
    • Efficacy and safety of recombinant human activated protein C for severe sepsis
    • Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
    • (2001) N Engl J Med , vol.344 , pp. 699-709
    • Bernard, G.R.1    Vincent, J.L.2    Laterre, P.F.3
  • 3
    • 0042031562 scopus 로고    scopus 로고
    • Drotrecogin alfa (activated) treatment of older patients with severe sepsis
    • Ely EW, Angus DC, Williams MD, et al: Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Clin Infect Dis 2003; 37:187-195
    • (2003) Clin Infect Dis , vol.37 , pp. 187-195
    • Ely, E.W.1    Angus, D.C.2    Williams, M.D.3
  • 4
    • 0037251585 scopus 로고    scopus 로고
    • Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis
    • The PROWESS investigators
    • Ely EW, Laterre PF, Angus DC, et al: The PROWESS investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31:12-19
    • (2003) Crit Care Med , vol.31 , pp. 12-19
    • Ely, E.W.1    Laterre, P.F.2    Angus, D.C.3
  • 5
    • 0037803423 scopus 로고    scopus 로고
    • Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple organ dysfunction: Data from the PROWESS trial
    • Dhainaut JF, Laterre PF, Janes JM, et al: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple organ dysfunction: Data from the PROWESS trial. Intensive Care Med 2003; 29:894-903
    • (2003) Intensive Care Med , vol.29 , pp. 894-903
    • Dhainaut, J.F.1    Laterre, P.F.2    Janes, J.M.3
  • 6
    • 8544268686 scopus 로고    scopus 로고
    • The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis
    • Angus DC, Laterre P-F, Heiterbrand J, et al: The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004; 32:2199-2206
    • (2004) Crit Care Med , vol.32 , pp. 2199-2206
    • Angus, D.C.1    Laterre, P.-F.2    Heiterbrand, J.3
  • 7
    • 8544284118 scopus 로고    scopus 로고
    • Hospital mortality and resource use in subgroups of the PROWESS trial
    • Laterre P-F, Levy H, Clermont G, et al: Hospital mortality and resource use in subgroups of the PROWESS trial. Crit Care Med 2004; 32:2207-2218
    • (2004) Crit Care Med , vol.32 , pp. 2207-2218
    • Laterre, P.-F.1    Levy, H.2    Clermont, G.3
  • 8
    • 8544221034 scopus 로고    scopus 로고
    • Drotrecogin alfa (activated) administration: Too many subgroups
    • Carlet J. Drotrecogin alfa (activated) administration: Too many subgroups. Crit Care Med 2003; 31:3564-3565
    • (2003) Crit Care Med , vol.31 , pp. 3564-3565
    • Carlet, J.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.